Immunopathogenesis of multiple sclerosis: New insights and therapeutic implications

CONTINUUM Lifelong Learning in Neurology

Volumn 16, Issue 5, 2010, Pages 166-180

  Awad, Amer M ^a   Stüve, Olaf ^a  

^a Archives of Neurology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BETA INTERFERON; BG00012; CD52 ANTIGEN; CENTRAL NERVOUS SYSTEM AGENTS; CLADRIBINE; DACLIZUMAB; GLATIRAMER; IMMUNOGLOBULIN G; INTERLEUKIN 13; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 5; LAQUINIMOD; MESSENGER RNA; MINOCYCLINE; MITOXANTRONE; MYELIN BASIC PROTEIN; NATALIZUMAB; RILUZOLE; RITUXIMAB; SPHINGOSINE 1 PHOSPHATE; TERIFLUNOMIDE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LATE ACTIVATION ANTIGEN 4;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; B LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MIGRATION; CELLULAR IMMUNITY; CEREBROSPINAL FLUID; DENDRITIC CELL; DISEASE PREDISPOSITION; DRUG EFFICACY; DRUG MEGADOSE; EOSINOPHIL; GENETICS; HELPER CELL; HLA SYSTEM; HUMAN; HUMORAL IMMUNITY; IMMUNOBIOLOGY; IMMUNOPATHOGENESIS; MONOCYTE; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY T LYMPHOCYTE; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TH17 CELL; TH2 CELL;

EID: 78650755985     PISSN: 10802371     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.CON.0000389940.92283.aa     Document Type: Article

References (85)

1. Hauser SL, Oksenberg JR. The neurobiology of multiple sclerosis: Genes, inflammation, and neurodegeneration. Neuron 2006;52(1):61-76.
2. Bo L, Geurts JJ, van der Valk P, et al. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol 2007;64(1):76-80.
3. Peterson LK, Fujinami RS. Inflammation, demyelination, neurodegeneration and neuroprotection in the pathogenesis of multiple sclerosis. J Neuroimmunol 2007;184(1-2):37-44.
4. Loeb JA. Neuroprotection and repair by neurotrophic and gliotrophic factors in multiple sclerosis. Neurology 2007;68(22 suppl 3):S38-S42; discussion S43-S54.
5. Frohman EM, Racke MK, Raine CS. Multiple sclerosis: The plaque and its pathogenesis. N Engl J Med 2006;354(9):942-955.
6. Kurtzke JF, Hyllested K. Multiple sclerosis in the Faroe Islands: I. clinical and epidemiological features. Ann Neurol 1979;5(1):6-21.
7. Cabre P, Signate A, Olindo S, et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005;128(pt 12):2899-2910.
8. Willer CJ, Dyment DA, Risch NJ, et al. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003;100(22):12877-12882.
9. Dyment DA, Ebers GC, Sadovnick AD. Genetics of multiple sclerosis. Lancet Neurol 2004;3(2):104-110.
10. Awad AB, Hemmer HP, Hartung B, et al. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol 2010;219(1-2):1-7.
11. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergicencephalomyelitis toresearch onmultiple sclerosis.AnnNeurol 2006;60(1):12-21.
12. O'Connor KC, McLaughlin KA, De Jager PL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 2007;13(2):211-217.
13. Lisak RP, Zweiman B. In vitro cell-mediated immunity of cerebrospinal-fluid lymphocytes to myelin basic protein in primary demyelinating diseases. N Engl J Med 1977;297(16):850-853.
14. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: Implications for the pathogenesis of demyelination. Ann Neurol 2000;47(6):707-717.
15. Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008;63(1):16-25.
16. Henderson AP, Barnett MH, Parratt JD, Prineas JW. Multiple sclerosis: Distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009;66(6):739-753.
17. Trapp BD, Nave KA. Multiple sclerosis: An immune or neurodegenerative disorder? Annu Rev Neurosci 2008;31:247-269.
18. Hafler D, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357(9):851-862.
19. Gregory SG, Schmidt S, Seth P, et al. Interleukin 7 receptor alpha chain (IL7R) shows allelic and functional association with multiple sclerosis. Nat Genet 2007;39(9):1083-1091.
20. Kleinschnitz C, Meuth SG, Kieseier BC, et al. Immunotherapeutic approaches in MS: Update on pathophysiology and emerging agents or strategies 2006. Endocr Metab Immune Disord Drug Targets 2007;7(1):35-63.
21. Charo IF, Ransohoff RM. The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006;354(6):610-621.
22. Delgado S, Sheremata WA. The role of CD4+ T-cells in the development of MS. Neurol Res 2006;28(3):245-249.
23. Chitnis T. The role of CD4 T cells in the pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007;79:43-72.
24. Laplaud DA, Berthelot L, Miqueu P, et al. Serial blood T cell repertoire alterations in multiple sclerosis patients; correlation with clinical and MRI parameters. J Neuroimmunol 2006;177(1-2):151-160.
25. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone: I. definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136(7):2348-2357.
26. Allen JE, Maizels RM. TH1-TH2: Reliable paradigm or dangerous dogma? Immunol Today 1997;18(8):387-392.
27. Gor DO, Rose NR, Greenspan NS. TH1-TH2: A procrustean paradigm. Nat Immunol 2003;4(6):503-505.
28. Harrington LE, Hatton RD, Mangan PR, et al. Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6(11):1123-1132.
29. Crawford MP, Yan SX, Ortega SB, et al. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004;103(11):4222-4231.
30. Shimonkevitz R, Colburn C, Burnham JA, et al. Clonal expansions of activated gamma/delta T cells in recent-onset multiple sclerosis. Proc Natl Acad Sci U S A 1993;90(3):923-927.
31. Owens GP, Bennett JL, Gilden DH, et al. The B cell response in multiple sclerosis. Neurol Res 2006;28(3):236-244.
32. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005;128(pt 7):1667-1676.
33. Harp C, Lee J, Lambracht-Washington D, et al. Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection. J Neuroimmunol 2007;183(1-2):189-199.
34. Corcione A, Casazza S, Ferretti E, et al. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 2004;101(30):11064-11069.
35. Winges KM, Gilden DH, Bennett JL, et al. Analysis of multiple sclerosis cerebrospinal fluid reveals a continuum of clonally related antibody-secreting cells that are predominantly plasma blasts. J Neuroimmunol 2007;192(1-2):226- 234.
36. Burns J, Rosenzweig A, Zweiman B, et al. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983;81(2):435-440.
37. Sakaguchi S, Powrie F. Emerging challenges in regulatory T cell function and biology. Science 2007;317(5838):627-629.
38. Viglietta V, Baecher-Allan C, Weiner HL, et al. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199(7):971-979.
39. Haas J, Hug A, Viehover A, et al. Reduced suppressive effect of CD4+ CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. Eur J Immunol 2005;35(11): 3343-3352.
40. Kumar M, Putzki N, Limmroth V, et al. CD4+CD25+FoxP3+ T lymphocytes fail to suppress myelin basic protein-induced proliferation in patients with multiple sclerosis. J Neuroimmunol 2006;180(1-2):178-184.
41. Huan J, Culbertson N, Spencer L, et al. Decreased FOXP3 levels in multiple sclerosis patients. J Neurosci Res 2005;81(1):45-52.
42. Feger U, Luther C, Poeschel S, et al. Increased frequency of CD4+ CD25+ regulatory T cells in the cerebrospinal fluid but not in the blood of multiple sclerosis patients. Clin Exp Immunol 2007;147(3):412-418.
43. Ruggieri M, Avolio C, Livrea P, et al. Glatiramer acetate in multiple sclerosis: A review. CNS Drug Rev 2007;13(2):178-191.
44. Teitelbaum D, Fridkis-Hareli M, Arnon R, et al. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neurol 1996;64(2):209-217.
45. Neuhaus O, Farina C, Wekerle H, et al. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 2001;56(6):702-708.
46. Dhib-Jalbut S, Chen M, Said A, et al. Glatiramer acetate-reactive peripheral blood mononuclear cells respond to multiple myelin antigens with a TH2-biased phenotype. J Neuroimmunol 2003;140(1-2):163-171.
47. Ragheb S, Abramczyk S, Lisak D, et al. Long-term therapy with glatiramer acetate in multiple sclerosis: Effect on T-cells. Mult Scler 2001;7(1):43-47.
48. Weber MS, Prod'homme T, Youssef S, et al. Type II monocytes modulate T cell-mediated central nervous system autoimmune disease. Nat Med 2007;13(8):935-943.
49. Miller A, Spada V, Beerkircher D, et al. Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis. Mult Scler 2008;14(4):494-499.
50. Wolinsky JS, Narayana PA, O'Connor P, et al. Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.
51. Hartung HP. Early treatment and dose optimisation BENEFIT and BEYOND. J Neurol 2005;252(suppl 3):iii44-iii50.
52. Borden EC, Sen GC, Uze G, et al. Interferons at age 50: Past, current and future impact on biomedicine. Nat Rev Drug Discov 2007;6(12):975-990.
53. Hartung HP, Bar-Or A, Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS? J Neurol 2004;251(suppl 5):v12-v29.
54. Rudick RA, Cutter G. Interferon-beta for multiple sclerosis: Long-term benefits? Ann Neurol 2007;61(4):283-285.
55. Pozzilli C, Prosperini L, Sbardella E, et al. Interferon after 10 years in patients with multiple sclerosis. Neurol Sci 2006;27(suppl 5):S369-S372.
56. Leussink VI, Zettl UK, Jander S, et al. Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis. Acta Neuropathol 2002;103(2):131-136.
57. Stüve O, Bennett JL. Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. CNS Drug Rev 2007;13(1):79-95.
58. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910.
59. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-923.
60. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 2006;354(9):924-933.
61. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003;348(1):15-23.
62. Bennett JL. Natalizumab and progressive multifocal leukoencephalopathy: Migrating towards safe adhesion molecule therapy in multiple sclerosis. Neurol Res 2006;28(3):291-298.
63. Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 2007;13(4):182-187.
64. Durr FE, Wallace RE, Citarella RV. Molecular and biochemical pharmacology of mitoxantrone. Cancer Treat Rev 1983;10(suppl B):3-11.
65. Ehninger G, Proksch B, Heinzel G, Woodward DL. Clinical pharmacology of mitoxantrone. Cancer Treat Rep 1986;70(12):1373-1378.
66. Millefiorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244(3):153-159.
67. Hartung HPR, Gonsette N, Konig H, et al. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360(9350):2018-2025.
68. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence report: The efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74(18):1463-1470.
69. Havrdova E. Aggressive multiple sclerosis: Is there a role for stem cell transplantation? J Neurol 2005;252(suppl 3):iii34-iii37.
70. Sun W, Popat U, Hutton G, et al. Characteristics of T-cell receptor repertoire and myelin-reactive T cells reconstituted from autologous haematopoietic stem-cell grafts in multiple sclerosis. Brain 2004;127(pt 5):996-1008.
71. Ratzinger G, Reagan JL, Heller G, et al. Differential CD52 expression by distinct myeloid dendritic cell subsets: Implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft host interactions in transplantation. Blood 2003;101(4):1422-1429.
72. De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007;58:417-432.
73. Coles AJ. Alemtuzumab improved multiple sclerosis functional composite scores and delayed time to first relapse at 2-year interim analysis compared to subcutaneous interferon beta-1a. In: 23rd Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS). 2007.
74. Hartman WR, Hentosh P. The antileukemia drug 2-chloro-20-deoxyadenosine: An intrinsic transcriptional antagonist. Mol Pharmacol 2004;65(1):227-234.
75. Sipe JC. Cladribine for multiple sclerosis: Review and current status. Expert Rev Neurother 2005;5(6):721-727.
76. Cross AH, Stark JL, Lauber J, et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006;180(1-2):63-70.
77. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-688.
78. Hawker KP, O'Connor MS, Freedman PA, et al. Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009;66(4):460-471.
79. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004;101(23):8705-8708.
80. Rose JW, Watt HE, White AT, et al. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann Neurol 2004;56(6):864-867.
81. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2R alpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci U S A 2006;103(15):5941-5946.
82. Brinkmann V, Cyster JG, Hla T. FTY720: Sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am J Transplant 2004;4(7):1019-1025.
83. Polman C, Barkhof F, Sandberg-Wollheim M, et al. Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. Neurology 2005;64(6):987-991.
84. O'Connor PW, Li D, Freedman MS, et al. A phase II study of the safety and efficacy of teriflunomide in multiple sclerosis with relapses. Neurology 2006;66(6):894-900.
85. Wakkee M, Thio HB. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate. Curr Opin Investig Drugs 2007;8(11):955-962.